Stay updated with breaking news from Graybug Vision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares dropped 2.3% during mid-day trading on Wednesday . The company traded as low as $2.15 and last traded at $2.15. Approximately 374 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 2,165 shares. The stock had previously closed at […]
The increasing diagnosed prevalence, and the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for RVO patients will drive the retinal vein occlusion market growth in the forecast period (2023–2032).New York, USA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight The increasing diagnosed prevalence, and the development of well-design
New York, USA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight The increasing diagnosed